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Abstract
Background: Overactivity and/or dysregulation of the endocannabinoid system (ECS) contribute to development
of obesity. In vitro studies indicate a regulatory role for the cannabinoid receptor 1 (CB1) in adipocyte function and
CB1-receptor deficient (CB1
-/-) mice are resistant to high fat diet-induced obesity. Whether this phenotype of CB1
-/-
mice is related to altered fat metabolism in adipose tissue is unknown.
Methods: We evaluated adipose tissue differentiation/proliferation markers and quantified lipogenic and lipolytic
activities in fat tissues of CB1
-/- and CB1
+/+ mice fed a high-fat (HF) or a high-fat/fish oil (HF/FO) diet as compared
to animals receiving a low-fat chow diet. Comparison between HF diet and HF/FO diet allowed to investigate the
influence of dietary fat quality on adipose tissue biology in relation to CB1 functioning.
Results: The adiposity-resistant phenotype of the CB1
-/- mice was characterized by reduced fat mass and adipocyte
size in HF and HF/FO-fed CB1
-/- mice in parallel to a significant increase in energy expenditure as compared to CB1
+/+ mice. The expression levels of adipocyte differentiation and proliferation markers were however maintained in
these animals. Consistent with unaltered lipogenic gene expression, the fatty acid synthesis rates in adipose tissues
from CB1
-/- and CB1
+/+ mice were unchanged. Whole-body and adipose-specific lipoprotein lipase (LPL) activities
were also not altered in CB1
-/- mice.
Conclusions: These findings indicate that protection against diet-induced adiposity in CB1-deficient mice is not
related to changes in adipocyte function per se, but rather results from increased energy dissipation by oxidative
and non-oxidative pathways.
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Background
The endocannabinoid system (ECS) comprises the endo-
genous cannabinoids (endocannabinoids or ECs), the can-
nabinoid receptors and the enzymes involved in the
synthesis and degradation of endocannabinoids [1]. The
two most studied ECs anandamide (AEA) and 2-arachido-
noyl glycerol (2-AG) are amides and esters, respectively, of
long-chain polyunsaturated fatty acids (PUFAs) [2]. To
date, two G protein-coupled cannabinoid receptors have
been identified. Because of its role in the central regulation
of food intake and energy balance, the cannabinoid 1
(CB1)-receptor has emerged as an interesting drug target
for treatment of obesity, dyslipidemia and insulin resis-
tance. CB2-receptors, on the other hand, are mainly
involved in immune function [3]. Administration of (endo)
cannabinoids increases food intake, while CB1-receptor
antagonism results in hypophagia [4]. Mice deficient for
the cannabinoid 1 receptor gene (Cnr1, further announced
as CB1
-/- mice) are lean and have less fat stores compared
to their wild type littermates [5]. This reduction in adipos-
ity appears to be independent of food intake [5], suggest-
ing that CB1 deficiency alters the balance between energy
intake, utilization and storage.
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nerves and several peripheral organs [3]. Adipose tissue
represents an important peripheral node of the ECS and
several in vitro studies indicate that CB1-receptor activ-
ity is critical for adipocyte function [5-7]. CB1 expres-
sion has been reported to increase during adipocyte
maturation [8] and ECs are required for adipocyte dif-
ferentiation and growth [6,9,10]. ECS signalling in adi-
pocytes supposedly promotes lipid storage [6,11-13]via
the induction of lipogenic genes and by increasing fatty
acid uptake [5,6]. Accordingly, CB1-receptor antagonists
arrest adipocyte proliferation and reduce lipogenic gene
expression [6,13]. Since growth retardation in CB1
-/-
mice is already apparent during the first weeks of life
[5], appropriate CB1-receptor functioning may be critical
for adipose tissue development in vivo.
Because EC receptor signalling impacts on energy bal-
ance, overactivity and/or dysregulation of the ECS have
been proposed contribute to the development of obesity
[7,11,14]. High-fat feeding induces obesity in rodents and
has been reported to increase the EC tone in their adi-
pose tissue [11,15] while CB1-deficient mice are resistant
to high-fat diet-induced obesity [16]. Besides their effects
on systemic energy expenditure, adipocyte-specific
actions of the cannabinoid receptors potentially impact
on adipose tissue physiology and thereby determine the
degree of fat storage. Different types of dietary fats exert
specific effects on body weight regulation [17] and n-3
PUFAs have been shown to decrease EC levels in adipo-
cytes [18]. In vitro studies indicate that enhanced CB1-
receptor signalling directs metabolism towards fat storage
[6,11] while reducing fat oxidation [7,11,19]. In addition,
it has been shown that peripheral CB1-receptor antagon-
ism reduces the expression of lipogenic genes in mice fed
a high-fat diet [20]. The protection against diet-induced
obesity in CB1-deficient mice may therefore, at least in
part, be related to changes in fat cell metabolism in these
animals. Very few studies have however systematically
evaluated the consequences of CB1 ablation for adipocyte
biology in vivo. Furthermore, it is unknown whether
CB1-receptor mediated changes in adipose tissue func-
tion contribute to high-fat diet induced obesity in
rodents.
We therefore investigated whether resistance to diet-
induced adiposity in CB1-deficient mice was related to
functional changes in adipocyte biology. In order to eval-
uate the influence of dietary fat quality in relation to CB1
functioning in adipose tissue, we determined the expres-
sion levels of differentiation and proliferation markers,
the rate of fatty acid synthesis and lipoprotein lipase
(LPL) activity in epididymal fat pads of CB1
+/+ and CB1
-/-
mice receiving a standard, low-fat chow diet, a high-fat
(HF) or a HF diet in which part of the fat was replaced by
fish oil (HF/FO diet). The results from this study indicate
that obesity-resistance in CB1-deficient mice is not
related to changes in adipocyte metabolism, but rather
results from increased energy expenditure.
Methods
Animals and experimental design
Initial breeding pairs for the generation of cannabinoid 1
receptor gene (Cnr1, further announced as CB1)k n o c k -
out mice were kindly provided by prof. dr. A. Zimmer,
Laboratory of Molecular Neurobiology, Department of
Psychiatry, University of Bonn, Germany. Male CB1
+/+
and CB1
-/- mice on a pure C57BL/6N background were
bred within our own facility from heterozygous crossing.
Animals were housed under light- and temperature-con-
trolled conditions (lights on 4:00 AM-4:00 PM, 21°C)
with free access to food and drinking water. From four
weeks of age onwards, they were divided into groups
and fed three different diets during six weeks. All diets
were obtained from Abdiets, Woerden, The Nether-
lands. One group received normal laboratory chow
(RMH-B), the second group received high-fat (HF; beef
tallow) diet and the third group received a diet in which
42% (w/w) of the beef tallow was replaced by fish oil
(HF/FO diet; menhaden oil). For diet composition see
Additional File 1 Table S1. The HF/FO diet was
renewed three times per week to prevent oxidation.
Body weight and food intake were registered regularly.
Separate cohorts of mice were generated to evaluate the
effects on basal parameters, energy expenditure, lipo-
genic fluxes and lipolytic activities. Prior to all experi-
ments, mice were subjected to a short postprandial
fasting period of 3 hours (6-9 AM) with drinking water
available to exclude acute postprandial effects without
the induction of a fasting response. Experimental proce-
dures were approved by the Ethics Committees for Ani-
mal Experiments of the University of Groningen.
Determination of body composition by whole-body
carcass analysis
During the 5
th week of dietary intervention, feces were
collected over a 72-hour period. Fecal energy content
was determined as previously described [21]. After six
weeks of diet, animals were fasted (6-9 AM) and blood
glucose concentrations were measured using a gluc-
ometer (Lifescan Benelux, Beerse, Belgium). Then, the
mice were sacrificed by cardiac puncture under isoflur-
ane anaesthesia and subcutaneous, epididymal, retroperi-
toneal and brown adipose fat depots were first collected
and weighed to determine their mass. Intestine, organs,
skin, and the remaining carcass including the head were
separately collected to determine mesenteric, organ, non-
removable subcutaneous and muscular fat mass, respec-
tively. Therefore, these samples were dried until all moist
was evaporated, after which the total (lean+fat) masses
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using Soxleth petroleum ether distillation. Then, the
samples were again dried, after which the fat free masses
were determined. The fat mass from the different sam-
ples was finally calculated by subtracting the lean mass
from the total mass.
Fat cell histology, basal plasma metabolite and gene
expression analysis
Epididymal adipose tissue was quickly removed, snap-fro-
zen in liquid nitrogen and stored at -80°C. Part of the fat
tissue was fixed in 4% paraformaldehyde in PBS and
embedded in paraffin. For adipocyte histology, 3 μmp a r -
affin sections were stained with hematoxylin and eosin
and analyzed at 10× magnification. The area of 240-420
fat cells per group was quantified using image analysis
software (Qwin, Leica, Wetzlar, Germany). Fat cell area
data were analyzed using the percent relative cumulative
frequency (PCRF) approach and EC50 values were calcu-
lated according to Riachi et al.[ 2 2 ] .A d i p o s et i s s u e -
derived LPL activity was determined as described under
‘lipolytic activity’. Blood was centrifuged (4000 × g for 10
minutes at 4°C) and plasma was stored at -20°C. Plasma
insulin, triglyceride, cholesterol and free fatty acids were
quantified using commercially available kits (Mercodia,
Uppsala, Sweden for insulin ELISA; Roche diagnostics,
Mannheim, Germany for triglyceride and cholesterol;
Wako Chemicals, Neuss, Germany for free fatty acids).
Plasma leptin, resistin and adiponectin concentrations
were determined by Luminex
® Multiplex technology
(Luminex Corporation, Austin, TX) using Multiplex
Immunoassays (Millipore, Amsterdam, The Netherlands)
[23]. RNA was extracted from adipose tissue using Tri
reagent (Sigma-Aldrich, St. Louis, MO) and subsequently
converted into cDNA by a reverse transcription proce-
dure using M-MLV and random primers according to
the manufacturer’s protocol (Sigma-Aldrich). For quanti-
tative PCR (qPCR), cDNA was amplified using the appro-
priate primers and probes. The sequences for all primers
and probes are given in Additional File 1 Table S2, and
those that have been published are deposited at RTpri-
merdB http://www.rtprimerdb.org/. All mRNA levels
were calculated relative to the expression of cyclophilin
and normalized for expression levels of chow-fed CB1
+/+
mice.
Indirect calorimetry
Homecage-housed animals were placed in an indirect
calorimeter chamber with free access to food and drink-
ing water. During 24 hours, gas exchange measurements
were performed using an eight-channel open flow sys-
tem. Flow rates were measured and controlled by a
mass flow controller. O2 and CO2 concentrations of
dried inlet and outlet air from each chamber were
measured at 10-minute intervals using a paramagnetic
O2 detector and an infrared CO2 detector. Estimated
energy expenditure in kcal/24 hours was calculated
using the following equation, which was derived from
[24,25]: (24 * (16.18*VO2*0.001) + (5.02*VCO2*0.001))/
4.184, with VO2 and VCO2 expressed in mL/h.
Fat and carbohydrate oxidation in mg/h were calcu-
lated using the following equation, which was derived
from [26]:
Fat oxidation: 38.461*VO2 -V C O 2,w i t hV O 2 and
VCO2 expressed in mol/h.
Carbohydrate oxidation: 94.017*VCO2 - 66.239*VO2,
with VO2 and VCO2 expressed in mol/h.
Data were calculated per animal or normalized for
total lean body mass, which was determined by carcass
analysis. Total lean mass represents the actual dry lean
mass, and was calculated by adding the lean masses
from intestine, organs, skin and carcass. Raw calorime-
try- and detailed substrate utilization data are presented
in Additional File 1 Figure S1A-S1C and Additional File
1 Table S3, respectively.
Determination of de novo lipogenesis and chain
elongation in adipose tissue
The assessment of lipogenic fluxes and chain elongation
is derived from the enrichment of the adipose tissue
acetyl-CoA precursor pool used for fatty acid synthesis
using non-radioactive steady state isotope labelling.
Lipogenic fluxes were calculated from the incorporation
of
13C-labelled acetate into palmitate, stearate and oleate
molecules within the adipose tissue [27,28]. In order to
determine these parameters, animals received sodium
[1-
13C]-acetate (99 atom %, Isotec/Sigma-Aldrich) via
the drinking water (2%) during the final 72 hours of the
dietary period. After a postprandial fast, mice were
sacrificed by cardiac puncture under isoflurane anaes-
thesia. Epididymal adipose tissue was quickly removed,
s n a p - f r o z e ni nl i q u i dn i t r o g e na n ds t o r e da t- 8 0 ° C .
Lipids were hydrolyzed in HCl/acetonitrile (1:22 v/v) for
45 minutes at 100°C. Fatty acids were extracted in hex-
ane and derivatized for 15 minutes at room temperature
using a-Br-2,3,4,5,6-pentafluorobenzyl (PFB)/acetoni-
trile/triethanolamine (1:6:2 v/v). Derivatization was
stopped by adding HCl and fatty acid-PFB derivatives
were extracted in hexane. The fatty acid-PFB mass iso-
topomer distributions were measured using an Agilent
5975 series GC/MSD (Agilent Technologies, Santa
Clara, CA). Gas chromatography was performed using a
ZB-1 column (Phenomenex, Torrance, CA). Mass spec-
trometry analysis was performed by electron capture
negative ionization using methane as moderating gas.
The normalized mass isotopomer distributions mea-
sured by GC-MS (m0-mx) were corrected for natural
abundance of
13C by multiple linear regression [29] to
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mers (M0-Mx) due to incorporation of [1-
13C]-acetate.
This distribution was used in mass isotopomer distribu-
tion analysis (MIDA) algorithms to calculate the acetyl-
CoA precursor pool enrichment (pacetate), fractional pal-
mitate synthesis rates (fC16:0) and the fraction of stearate
and oleate generated by elongation of de novo synthe-
sized palmitate (fC18:0/1(C16DNL)), or by elongation of pre-
existing palmitate (fC18:0/1(C16PE)) as described [28].
Lipolytic activity
Following the postprandial fast, a baseline blood sample
was drawn by retro-orbital bleeding under isoflurane
anaesthesia into heparinized capillaries. Mice subse-
quently received an intra-orbital injection of heparin in
saline (0.1 U/g body weight). After 10 minutes, a post-
heparin blood sample was drawn by retro-orbital bleed-
ing. Mice were sacrificed by cardiac puncture and blood
was centrifuged (4000 × g for 10 minutes at 4°C). Total
lipase activities were determined by incubating 10 μLo f
plasma with 200 μL of ultrasonified substrate containing
1 mL Triton X-100 (1%), 1 mL Tris.HCl (1 M), 2 mL of
heat-inactivated human serum, 2 mL of fat-free BSA
(10%), 42 mg triolein and 5 μL glycerol-tri-9,10(n)-[
3H]-
oleate (5 mCi/mL), with or without addition of 50 μL
NaCl (5 M) to block LPL activity. After 30-min incuba-
tion at 37°C, lipolysis was stopped by adding 3.25 mL of
heptane/methanol/chloroform (100:128:137, vol/vol/vol)
and 1 mL of 0.1 M K2CO3. After centrifugation for 15
min at 3,600 rpm at room temperature, extracted hydro-
lyzed fatty acids were quantified by scintillation counting.
Lipase activities were calculated according to the for-
mula: [disintegrations per second (dps) sample - dps
blank]/dps 200 μL LPL-substrate * factor, in which the
factor = {2.45 (volume aqueous phase) * 2.85 (total added
free fatty acids in micromoles)/[0.76 (extraction effi-
ciency) * 0.5 (reaction time in hours) * 0.01 (plasma
volume in mL)]}. Postheparin LPL activity was calculated
by subtracting postheparin hepatic lipase activity (i.e.,
lipase activity inhibited by 1 M NaCl) from the total post-
heparin lipase activity.
Adipose tissue specific LPL activity was determined in
biopsies collected after a postprandial fast. Tissue was first
homogenized in 1 mL of a buffer containing sucrose (0.25
M), EDTA (1 mM), Tris.HCl (10 mM) and Deoxycholate
(12 mM), pH 7.4 [30]. Tissue homogenates were centri-
fuged (20 min at 12000 × g for at 4°C) and the fraction
between the upper fat layer and the bottom sediment was
collected. Lipase activities were determined as described
using 50 μl of tissue fraction. LPL activity was calculated
by subtracting lipolytic activity determined in a final NaCl
concentration of 0.83 M (non-LPL) from total lipolytic
activity measured without NaCl. Data obtained in adipose
tissue were normalized for protein concentration [30].
Statistics
All data are presented as mean values ± SEM. Statistical
analysis was performed using SPSS for Windows software
(SPSS 16.0, Chicago, IL, USA). All parameters were first
tested for equality of variances by Levene’s test. Then, full-
factorial General Linear Model analysis was performed to
test for overall changes caused by diet or genotype, or for
interactions between diet and genotype. Data were there-
fore initially analysed with a large statistical power to ana-
lyse overall effects, using groups of n > 10. For the overall
dietary effects, Bonferoni post-hoc analysis was applied to
correct for multiple comparisons. Outcome of general lin-
ear model analysis is given in the legends. Independent
Student t-tests were run to analyse differences between
genotypes within diets, and between dietary groups within
genotypes. In the few cases where data transformation did
not result in equality of variance, non-parametric analysis
was performed. The null hypothesis was rejected at the
0.05 level of probability. Fat cell areas were considered sig-
nificantly different between groups if the 95%-confidence
intervals of the EC50 values obtained by PCRF analysis did
not overlap.
Results
The resistance against high-fat diet-induced adiposity in
CB1
-/- mice is associated with increased energy
expenditure and reduced adipocyte size
We first evaluated the adiposity-inducing effects of two
high-fat diets in young CB1
+/+ and CB1
-/- mice. Immedi-
ately after weaning, a 6-week dietary intervention was
started during which animals were fed chow, HF or HF/
FO diets. Body weight development during this interven-
tion is presented in Figure 1A. We observed a steep
increase in body weight during the first weeks of the diet-
ary intervention in all groups, which likely indicates
growth. Body weight development in this study therefore
reflects both growth and increasing adiposity. Body mass
was however always lower in CB1-deficient mice as com-
pared to wild-type littermates, irrespective of the diet they
received (Figure 1A). During the final weeks of the inter-
vention, body weight curves of CB1
+/+ and CB1
-/- mice
diverged, particularly in the HF and HF/FO group (Figure
1A). To assess to what extent the difference in body
weight reflected changes in adiposity, we quantified the fat
mass after finalisation of the dietary intervention. As
expected, HF and HF/FO feeding resulted in a comparable
increase in fat mass compared to chow in CB1
+/+ mice,
while CB1
-/- mice remained relatively lean on the HF and
HF/FO diets (Figure 1B). Whole-body carcass analysis
revealed that, with the exception of brown fat, all adipose
tissue depots contributed to the diet-induced adiposity
(Table 1). Caloric intake was significantly higher in HF
and HF/FO fed CB1
+/+ and CB1
-/- mice as compared to
chow-fed controls (Figure 1C). The resistance to adiposity
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http://www.nutritionandmetabolism.com/content/8/1/93
Page 4 of 12in CB1
-/- mice was however independent of caloric intake
since we did not observe differences in energy consump-
tion between CB1
+/+ and CB1
-/- mice during the dietary
interventions (Figure 1C). Fecal energy loss was also simi-
lar in CB1
+/+ and CB1
-/- mice, indicating that intestinal
energy absorption was comparable (Figure 1D). Fish oil
replacement, however, increased nutrient absorption in
HF-fed mice, since fecal energy loss was reduced in
CB1
+/+ and CB1
-/- mice that were fed the HF/FO diet.
A linear relationship between body weight and energy
expenditure was observed for chow-fed CB1
+/+ and
CB1
-/- mice only (data not shown), indicating that the
increase in body weight upon HF and HF/FO feeding
was not accompanied by elevated energy expenditure
in this study. Nevertheless, we found that estimated
energy expenditure was clearly and significantly
increased in HF and HF/FO-fed CB1-deficient mice as
compared to wild-type controls (Figure 1E and Addi-
tional File 1 Table S3). Altogether, analysis of the dif-
ferent components of energy balance (Figures 1C-E)
reveals equal energy intake and -expenditure in chow-
fed CB1
+/+ and CB1
-/- mice. On the other hand, HF
and HF/FO feeding induced a positive energy balance,
which is less marked in CB1
-/- versus CB1
+/+ mice, as a
result of increased energy expenditure. Interestingly,
chow-fed CB1
-/- mice exhibited higher fat oxidation
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Figure 1 Body weight, fat mass and energy balance in CB1
+/+ and CB1
-/- mice fed chow, a HF or a HF/FO diet during 6 weeks. A, Body
weight development during the dietary intervention. B, Total fat mass at the end of the dietary intervention. C, Caloric intake, determined by
manual food weighing, and averaged over the third to fifth week of dietary intervention. D, Fecal energy loss and E, Energy expenditure, derived
from indirect calorimetry. Open symbols/bars, CB1
+/+ mice; closed symbols/bars, CB1
-/- mice. Values are given as means ± SEM for n = 5-13; # p <
0.05 compared to chow group of the same genotype; $ p < 0.05 compared to HF group of the same genotype, * p < 0.05 CB1
-/- vs. CB1
+/+
(Student t-test). General linear model analysis revealed overall effects for the following parameters (p < 0.05): Genotype: body weight at every
timepoint, total fat mass, 24 h-energy expenditure. Chow versus HF: total fat mass, caloric intake, 24 h-energy expenditure. Chow versus HF/FO:
total fat mass, caloric intake, fecal energy loss. HF versus HF/FO: caloric intake, fecal energy loss.
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which likely explains the lower fat mass as compared
to CB1
+/+ m i c e( F i g u r e1 Ba n dT a b l e1 ) .
HF and HF/FO feeding led to an increase in adipocyte
size in both CB1
+/+ and CB1
-/- mice (Figure 2A and 2B).
Similar to body and fat mass, CB1
-/- mice always had
smaller adipocytes (Figure 2A), and we observed a signifi-
cant difference between the 95%-confidence intervals of
the fat cell area EC50s in CB1
-/- versus CB1
+/+ mice fed
either of the three diets (Figure 2B). Adipose tissue
expression of Faah, Pparg2, C/ebpa, Ap2 and Adiponec-
tin were not affected by CB1 deficiency or HF and HF/
FO feeding, while Napepld expression was increased in
HF-fed mice of both genotypes (Table 2). Plasma trigly-
ceride, insulin, adiponectin and resistin levels were com-
parable in all mice (Table 1). Cholesterol concentrations
were increased in HF-fed CB1
+/+ and CB1
-/- mice as com-
pared to those receiving chow, and normalized in HF/
FO-fed mice (Table 1). Non-esterified fatty acid levels
were significantly lower in chow- and HF/FO-fed CB1-
deficient mice (Table 1). Glucose levels tended to be
lower in CB1
-/- versus CB1
+/+ mice, however the differ-
ence reached statistical significance for HF-fed animals
only (Table 1). Plasma leptin concentrations (Table 1)
correlated to the degree of HF and HF/FO-induced adip-
osity (Figure 1B) in CB1
+/+ and CB1
-/- mice.
Fatty acid synthesis in adipose tissue is not affected in
CB1
-/- mice
To assess whether lipogenesis was reduced in CB1
-/-
mice, we determined fatty acid synthesis in adipose tissue
using
13C-acetate incorporation. Acetyl-CoA pool enrich-
ments were increased in HF-fed CB1
+/+ and CB1
-/- mice
as compared to chow-fed animals (Figure 3A), and nor-
malized by FO replacement in both genotypes. No differ-
ences between CB1
+/+ and CB1
-/- mice were observed. De
novo palmitate synthesis was similar in CB1
+/+ and CB1
-/-
mice, but was reduced in mice fed the HF and HF/FO
diets as compared to chow-fed animals (Figure 3B). Simi-
larly, fractional synthesis of stearate and oleate via de
novo lipogenesis was reduced in CB1
+/+ and CB1
-/- mice
f e dt h eH Fa n dH F / F Od i e t sa sc o m p a r e dt oc h o w - f e d
animals (Figure 3C and 3D) with no differences between
CB1
+/+ and CB1
-/- m i c e .C o m p a r e dt oH F - f e dm i c e ,de
novo stearate synthesis was slightly increased in HF/FO-
fed mice of both genotypes (Figure 3C). The unaltered
fatty acid synthesis rates in CB1
-/- mice were supported
by gene expression analysis in adipose tissue: we did not
Table 1 Body composition and plasma metabolite concentrations in CB1
+/+ and CB1
-/- mice fed chow, a HF or a HF/FO
diet during 6 weeks
chow HF HF/FO
CB1
+/+ CB1
-/- CB1
+/+ CB1
-/- CB1
+/+ CB1
-/-
Subcutaneous fat (g) 0.9 ± 0.1 0.7 ± 0.0 2.1 ± 0.3# 1.1 ± 0.1#* 2.5 ± 0.4# 1.4 ± 0.1#*
Epididymal fat (mg) 319 ± 40 227 ± 19 716 ± 113# 361 ± 34#* 644 ± 85# 406 ± 64#*
Retroperitoneal fat (mg) 116 ± 17 66 ± 6* 217 ± 33# 108 ± 7#* 300 ± 54# 145 ± 19#*
Brown fat (mg) 45 ± 6 41 ± 5 47 ± 6 36 ± 3 52 ± 5 36 ± 5
Mesenteric fat (mg) 194 ± 18 148 ± 12 303 ± 36# 181 ± 11* 336 ± 47# 190 ± 14*
Muscular fat (g) 0.6 ± 0.0 0.5 ± 0.0* 1.0 ± 0.1# 0.7 ± 0.0#* 1.1 ± 0.1# 0.8 ± 0.0#*
Organ fat (mg) 113 ± 15 103 ± 14 176 ± 28 161 ± 15# 238 ± 30# 133 ± 14*
Lean mass (g) 5.2 ± 0.6 4.6 ± 0.1* 5.0 ± 0.1 4.7 ± 0.1 5.0 ± 0.1 4.7 ± 0.1
Plasma metabolites and adipokines
Triglycerides (μM) 333 ± 31 245 ± 31 277 ± 29 275 ± 33 240 ± 63 183 ± 19
Cholesterol (mM) 1.3 ± 0.2 0.9 ± 0.1 1.9 ± 0.1# 1.8 ± 0.1# 1.4 ± 0.1$ 1.3 ± 0.1#$
Non-esterified fatty acids (μM) 607 ± 32 391 ± 34* 586 ± 40 588 ± 51# 464 ± 38# 372 ± 26$
Blood glucose (mM) 9.3 ± 0.5 7.7 ± 0.8 9.1 ± 0.3 7.4 ± 0.4* 9.0 ± 0.4 8.1 ± 0.3
Insulin (pg/mL) 334 ± 53 356 ± 86 325 ± 39 270 ± 64 371 ± 82 300 ± 84
Leptin (ng/mL) 0.7 ± 0.1 0.6 ± 0.1$ 2.1 ± 0.5#* 1.0 ± 0.2#* 2.2 ± 0.5# 1.7 ± 0.3#
Adiponectin (μg/mL) 14.3 ± 1.3 18.5 ± 2.4 15.4 ± 1.5 17.0 ± 2.9 18.1 ± 2.2 19.1 ± 2.2
Resistin (ng/mL) 2.3 ± 0.2 2.5 ± 0.4 3.0 ± 0.5 2.9 ± 0.3 2.1 ± 0.2 2.6 ± 0.4
Values are given as means ± SEM for n = 6-8; # p < 0.05 compared to chow group of the same genotype; $ p < 0.05 compared to HF group of the same
genotype, * p < 0.05 CB1
-/- vs. CB1
+/+ (Student t-test).
General linear model analysis revealed overall effects for the following parameters (p < 0.05):
Genotype: subcutaneous/epidydimal/retroperitoneal/brown/mesenteric/muscular/organ fat mass, lean mass, non-esterified fatty acid levels, glucose levels.
Chow versus HF: subcutaneous/epididymal/retroperitoneal/mesenteric/muscular/organ fat mass, leptin levels.
Chow versus HF/FO: subcutaneous/epididymal/retroperitoneal/mesenteric/muscular/organ fat mass, cholesterol levels, leptin levels.
HF versus HF/FO: non-esterified fatty acid levels.
Interaction between genotype and diet: non-esterified fatty acid levels.
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Page 6 of 12observe any changes in lipogenic gene expression
between CB1
+/+ and CB1
-/- mice under the different diet-
ary conditions (Table 2). HF feeding did not affect Acc1,
Fas and Pepck (Table 2) expression. HF feeding induced
Scd1 expression in both CB1
+/+ and CB1
-/- mice while we
observed a tendency for an increased Srebp-1c expres-
sion. These inductions were normalized in HF/FO-fed
CB1
+/+ and CB1
-/- mice (Table 2). HF/FO feeding also
reduced Acc and Fas expression levels as compared to
HF (Table 2). Fatty acids are toxic molecules, which are
immediately processed after they enter cells to prevent
apoptosis [31]. Chain-elongation and desaturation of pre-
existing palmitate may therefore be used as a measure for
fatty acid entry [31]. In contrast to the reduced lipogenic
fluxes from elongation of de novo synthesized palmitate
(Figure 3B-3D), we did not observe any consistent differ-
ences in synthesis of stearate (Figure 3E) and oleate
(Figure 3F) from elongation of pre-existing palmitate
between CB1
+/+ and CB1
-/- mice. Reduced fatty acid
influx therefore does not explain the protection against
HF and HF/FO-induced adiposity in CB1-deficient mice.
This is further supported to the unchanged mRNA levels
of the fatty acid transporters Cd36 and Fatp4 in these
animals (Table 2).
Lipolytic activity is maintained in CB1
-/- mice
CB1-receptor agonist treatment enhances lipolytic activ-
ity in vitro [5]. As a consequence, CB1 deficiency may
result in a reduction of lipoprotein triglyceride lipolysis,
thereby limiting fat storage in adipose tissue and as such
protecting against adiposit y .Y e t ,t h ee x p r e s s i o no fLpl
and its stimulatory factor Gpihbp1 [32] in adipose tissue
were not affected by CB1 deficiency or HF and HF/FO
feeding (Table 2). In parallel, we determined LPL activ-
ities in CB1
+/+ and CB1
-/- mice fed either of the three
diets. In accordance with unaltered Lpl and Gpihbp1
mRNA levels, we observed that both post-heparin plasma
LPL activity and adipose tissue-derived LPL-activity were
similar in all groups (Figure 3G and 3H). The expression
levels of the LPL inhibitory proteins Angptl3, Angplt4,
ApoC1 and ApoC3 [32,33] were also unchanged between
genotypes (Table 2). Because macrophage products have
been shown to inhibit adipocyte differentiation [34], we
determined CD68 macrophage antigen expression. Con-
sistent with the unaltered mRNA levels of adipocyte dif-
ferentiation/proliferation markers, we found no
significant differences in Cd68 expression between CB1-
deficient and wild-type mice (Table 2). Finally, we did
not observe significant differences in adipose tissue
expression of Hsl, Atgl and Cpt1a between CB1
+/+ and
CB1
-/- mice (Table 2), suggesting that fatty acid release
and -oxidation were also not affected by CB1 deficiency.
Discussion
Overactivity and/or dysregulation of the EC system
potentially contribute to the development of obesity
[7,11,14]. Several in vitro studies point to the involve-
ment of the CB1-receptor in controlling adipocyte devel-
opment and metabolism [5-13]. Here, we report that the
protection against high-fat diet induced adiposity and a
concomitant reduced fat cell size in CB1-deficient mice
are not related to alterations in adipocyte differentiation
and proliferation markers, or to changes lipogenic fluxes
and lipoprotein lipolysis in fat tissue.
Diet-induced adiposity was prevented in CB1
-/- mice as
compared to wild-type littermates. Analysis of the
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Figure 2 Fat cell area in CB1
+/+ and CB1
-/- mice fed chow, a HF
or a HF/FO diet during 6 weeks. A, Representative pictures of
3 μm paraffin hematoxylin and eosin-stained sections (1 cm =
100 μm) and B, percent relative cumulative frequency (PCRF) curves
of 240-420 fat cell areas from adipose tissue sections. Inset: EC50
values of the PCRF curves and their 95%-confidence intervals. Open
symbols, CB1
+/+ mice; closed symbols, CB1
-/- mice. # p < 0.05
compared to chow group of the same genotype; $ p < 0.05
compared to HF group of the same genotype, * p < 0.05 CB1
-/- vs.
CB1
+/+ (p < 0.05 in case of no overlap between EC50 95%-
confidence intervals).
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Page 7 of 12energy balance in chow, HF and HF/FO-fed animals
revealed that CB1 deficiency did not impact on energy
intake. Consistent with previous findings [35], no major
effects on food intake were observed. Although both HF
and HF/FO feeding increased intestinal fatty acid
uptake, this occurred to a similar extent in CB1
-/- and
CB1
+/+ mice. Interestingly, isocaloric replacement of the
saturated fat in the HF diet for PUFA provoked an addi-
tional increase in intestinal fatty acid uptake. This most
likely resulted from an upregulation of intestinal fatty
acid transport proteins and a subsequent increase in
lipid uptake [36]. On the other hand, we observed that
energy expenditure was increased in HF and HF/FO-fed
CB1
-/- mice as compared to wild-type littermates.
Reduced diet-induced adiposity upon CB1 ablation was
therefore associated with a less positive energy balance
in the current study.
Impaired CB1-signalling has been shown to protect
against high-fat diet-induced obesity in adult mice
[16,35], however, the adipocyte-specific consequences in
this context had not been evaluated. The ECS has been
implicated in the regulation of adipocyte proliferation
and differentiation in vitro [5-13] and CB1-deficient mice
are retarded in growth from an early age on [5]. We
Table 2 Adipose tissue gene expression levels in CB1
+/+ and CB1
-/- mice fed chow, a HF or a HF/FO diet during 6 weeks
chow HF HF/FO
CB1
+/+ CB1
-/- CB1
+/+ CB1
-/- CB1
+/+ CB1
-/-
Endocannabinoid system
CB1 (Cnr1) 1.0 ± 0.1 ND 1.0 ± 0.1 ND 1.1 ± 0.2 ND
Napepld 1.0 ± 0.1 0.9 ± 0.1 1.4 ± 0.1# 1.3 ± 0.2# 1.2 ± 0.1 1.1 ± 0.1
Faah 1.0 ± 0.3 1.8 ± 0.5 1.1 ± 0.6 1.1 ± 0.4 1.0 ± 0.5 1.3 ± 0.6
Adipocyte proliferation and differentiation
Pparg2 (Pparg) 1.0 ± 0.2 1.0 ± 0.1 1.4 ± 0.1 1.2 ± 0.3 1.0 ± 0.1$ 0.9 ± 0.1
C/ebpa (Cebpa) 1.0 ± 0.1 1.0 ± 0.1 1.2 ± 0.0 1.3 ± 0.3 1.0 ± 0.1 0.9 ± 0.1
Ap2 (Fabp4) 1.0 ± 0.1 0.9 ± 0.1 1.5 ± 0.0# 1.2 ± 0.2 1.4 ± 0.1 1.2 ± 0.1
Adiponectin (Adipoq) 1.0 ± 0.2 0.9 ± 0.2 1.3 ± 0.1 1.3 ± 0.4 1.3 ± 0.1 1.0 ± 0.1
Trigyceride synthesis
Srebp-1c (Srebf1) 1.0 ± 0.1 1.2 ± 0.1 1.5 ± 0.1# 1.8 ± 0.4 1.1 ± 0.0$ 1.1 ± 0.0
Acc1 (Acaca) 1.0 ± 0.2 1.1 ± 0.3 0.9 ± 0.1 0.9 ± 0.3 0.6 ± 0.1$ 0.5 ± 0.1#
Fas (Fasn) 1.0 ± 0.2 1.1 ± 0.2 1.1 ± 0.1 1.0 ± 0.3 0.7 ± 0.1$ 0.4 ± 0.0#
Scd1 1.0 ± 0.1 0.9 ± 0.1 2.8 ± 0.1# 3.1 ± 0.7# 0.9 ± 0.1$ 1.1 ± 0.1$
Pepck (Pck1) 1.0 ± 0.2 0.9 ± 0.1 1.0 ± 0.1 1.3 ± 0.4 1.1 ± 0.1 0.9 ± 0.1
Fatty acid uptake and transport
Cd36 1.0 ± 0.1 1.1 ± 0.1 1.1 ± 0.0 1.2 ± 0.1 1.4 ± 0.2 1.1 ± 0.1
Fatp4 (Slc27a4) 1.0 ± 0.1 1.0 ± 0.1 1.2 ± 0.0 1.4 ± 0.2 1.2 ± 0.1 1.1 ± 0.1
Fatty acid hydrolysis
Lpl 1.0 ± 0.3 0.9 ± 0.2 1.2 ± 0.1 0.9 ± 0.2 1.4 ± 0.2 1.0 ± 0.1
Gpihbp1 1.0 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.2 ± 0.1 1.3 ± 0.1 0.9 ± 0.0
Angptl3 1.0 ± 0.1 0.9 ± 0.1 1.2 ± 0.1 1.1 ± 0.1 1.0 ± 0.1 1.0 ± 0.0
Angptl4 1.0 ± 0.1 1.0 ± 0.1 1.3 ± 0.1 1.2 ± 0.1 1.5 ± 0.1 1.1 ± 0.1
Apoc1 1.0 ± 0.2 1.2 ± 0.1 1.1 ± 0.0 1.1 ± 0.0 0.7 ± 0.1$ 0.9 ± 0.1
Apoc3 1.0 ± 0.2 0.7 ± 0.1 0.6 ± 0.1 0.4 ± 0.0 0.2 ± 0.0$ 0.2 ± 0.0#
Macrophage infiltration
Cd68 1.0 ± 0.1 1.0 ± 0.1 1.2 ± 0.0 1.0 ± 0.1 1.3 ± 0.1 1.0 ± 0.1
Adipocyte lipolysis
Hsl (Lipe) 1.0 ± 0.2 1.1 ± 0.2 1.2 ± 0.1 1.0 ± 0.2 1.2 ± 0.1 1.1 ± 0.1
Atgl (Pnpla2) 1.0 ± 0.2 1.1 ± 0.2 1.5 ± 0.2 1.4 ± 0.4 1.2 ± 0.1 1.2 ± 0.2
Fatty acid oxidation
Cpt1a 1.0 ± 0.1 1.2 ± 0.2 1.6 ± 0.2# 1.2 ± 0.2 1.3 ± 0.1# 1.1 ± 0.1
Expression levels were normalized to cyclophilin expression and values are given as means ± SEM for n =4 - 8 ;#p < 0.05 compared to chow group of the same
genotype, $ p < 0.05 compared to HF group of the same genotype (Student t-test). ND, non-detectable.
General linear model analysis revealed overall effects for the following parameters (p < 0.05):
Chow versus HF: aP2, Scd1, Srebp-1c.
Chow versus HF/FO: Fas.
HF versus HF/FO: Fas, Scd1, Srebp-1c.
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Page 8 of 12therefore decided to study the metabolic consequences of
high-fat feeding in young CB1
-/- mice. Six weeks of HF
and HF/FO feeding induced adiposity in CB1
+/+ mice,
which was characterized by an increased fat mass and
adipocyte size. This effect was clearly blunted in CB1
-/-
mice, although these mice did become more obese on the
HF and HF/FO diets as compared to chow-fed CB1
-/-
mice. Gene expression analysis indicated that this was
not due to a lower expression of adipocyte differentiation
and proliferation markers in CB1
-/- mice, since we did
not observe differences in Pparg2, Cebp/a and Ap2
mRNA levels. The expression of these genes was also not
different prior to the start of the dietary interventions
(Additional File 1 Figure S1D).
PPARg and C/EBPa are two master transcription fac-
tors which play key roles in controlling adipocytes dif-
ferentiation and proliferation, as well as adiponectin
gene transcription [37,38]. We did not observe differ-
ences in adiponectin mRNA levels, indicating that, in
parallel to the unaltered expression levels of PPARg and
C/EBPa, the transcriptional activity of these regulators
was not impaired by CB1 deficiency. In accordance with
these findings, we observed that plasma adiponectin
concentrations remained unchanged among the different
groups studied. Because of the relatively short timeframe
of the dietary intervention, HF and HF/FO feeding did
not yet alter adiponectin levels as compared to chow-fed
mice [39]. Although CB1-receptor activity has been pro-
posed to modulate adiponectin expression and release
[7,11], pharmacological CB1-receptor activation and
blockade do not directly affect adiponectin expression in
cultured adipocytes [12,40]. The reported effects on adi-
ponectin expression and -secretion are therefore rather
related to acute changes in food intake [41]. Consistent
with the unchanged adiponectin levels and similar to
what has been found by others [35], voluntary caloric
intake was not different between CB1
+/+ and CB1
-/-
mice.
Pharmacological CB1-receptor activation promotes
lipid storage in adipocytes [6,11-13], in parallel to ele-
vated expression levels of lipogenic genes in fat tissue [6].
We therefore quantified the lipogenic flux in vivo in adi-
pose tissue of CB1
+/+ and CB1
-/- mice. Fatty acid synth-
esis rates were not affected by CB1 deficiency, in line
with unaltered expression levels of lipogenic genes. In
both genotypes, HF and HF/FO feeding reduced de novo
lipogenesis (indicated by lower fractional palmitate
synthesis as well as by reduced stearate and oleate synth-
esis from de novo synthesized palmitate). This is in agree-
ment with a report that shows reduced fatty acid
synthesis from glucose in the fat tissue of high-fat fed
mice compared to animals receiving a low-fat diet [42].
Thus, high-fat diet-induced adiposity is caused by
increased storage and elongation of dietary fatty acids.
The latter process was however not affected by CB1 defi-
ciency in the current study, since we found that fatty acid
elongation of pre-existing palmitate was maintained in
CB1
-/- mice. The obesity-resistant phenotype of these
CB1
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Figure 3 Fractional fatty acid synthesis rates and lipolytic
activities in CB1
+/+ and CB1
-/- mice fed chow, a HF or a HF/FO
diet during 6 weeks. A, Acetyl-CoA precursor pool enrichment. B,
De novo palmitate synthesis. C De novo stearate synthesis. D, De
novo oleate synthesis. E, Stearate synthesis from pre-existing
palmitate. F, Oleate synthesis from pre-existing palmitate. G, Post-
heparin plasma LPL activity and H, Adipose tissue-derived LPL
activity normalized for protein content. Open bars, CB1
+/+ mice;
closed bars, CB1
-/- mice. Values are given as means ± SEM for n =
4-7; # p < 0.05 compared to chow group of the same genotype;
$ p < 0.05 compared to HF group of the same genotype (Student
t-test). General linear model analysis revealed overall effects for the
following parameters (p < 0.05): Chow versus HF: acetyl-CoA pool
enrichment, de novo palmitate/stearate/oleate synthesis. Chow
versus HF/FO: de novo palmitate/stearate synthesis. HF versus HF/FO:
acetyl-CoA pool enrichment, de novo stearate/oleate synthesis.
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acid synthesis or -elongation.
Lipid supply to organs and tissues requires the activity
of lipases. Adipocyte-specific LPL activity directs fatty
acids to the adipose tissue, thereby enabling their sto-
rage. To assess whether the protection against high-fat
diet-induced adiposity in CB1
-/- mice was secondary to a
reduced lipolytic activity, we determined whole-body
and adipose tissue-specific LPL activity. CB1
+/+ and
CB1
-/- mice fed either of the three diets exhibited com-
parable LPL activities. Elevated plasma EC concentra-
tions have been associated with increased LPL activity
[43]. In vitro studies have furthermore shown that CB1-
receptor antagonism inhibits LPL activity in adipocytes,
however, only when these cells are co-treated with a
CB1-receptor agonist [5]. Together, these findings indi-
cate that CB1-receptor blockade only impacts on LPL
activity under conditions of active ECS signalling. Con-
sistent with previous work [35], we did not observe an
increase in LPL activity upon high-fat feeding. LPL
activity was furthermore not different between CB1
+/+
and CB1
-/- mice, suggesting that the HF diet did not
increase CB1-mediated LPL activity, which rendered this
process insensitive to CB1 ablation. In further support of
this were the unchanged expression levels of LPL and its
regulators among the different groups. Thus, the
reduced fat stores in CB1-deficient mice were not
related to impaired LPL-mediated lipolysis. The unal-
tered expression levels of Hsl and Atgl and the lack of
an increase in plasma non-esterified fatty acid levels in
CB1-deficient mice furthermore argues against increased
fatty acid release from adipose tissue in these animals.
Although several studies have implicated the ECS in
control of adipocyte differentiation/proliferation, lipo-
genesis and lipolysis [5-13], the current work excludes
the possibility that these processes contribute to the
development of obesity through CB1.O n eo ft h ee x p l a -
nations for these discrepancies presumably lies in the
acute and transient nature of responses to pharmacolo-
gical treatments [44], whereas our knockout mice rather
provide a model of sustained impaired CB1 activity. The
adaptations of adipocyte biology in response to altered
EC composition, on the other hand, are most likely
mediated by CB1-independent mechanisms. Overall, our
data indicate that the reported physiological changes in
adipocyte biology that occur in response to altered ECS
activity cannot explain the phenotype of CB1
-/- mice in
the long term.
Reduced diet-induced fat storage in CB1
-/- mice was
primarily related to a less positive energy balance as
compared to their wild type littermates in this study.
Recent reports show that decreased ECS signalling pro-
motes energy dissipation as heat. CB1-receptor blockade
induces a mitochondria-rich, thermogenic phenotype in
adipocytes, characterized by increased mitochondrial
uncoupling [45-48]. CB1-agonists, on the other hand,
impair mitochondrial biogenesis and -uncoupling [6,49].
Therefore, both oxidative and non-oxidative energy
expenditure presumably contribute to the protection
against diet-induced adiposity CB1-deficient mice.
Conclusions
This study shows that the obesity-resistant phenotype of
CB1-deficient mice is not due to changes in adipose tis-
sue differentiation and -proliferation, lipogenesis or
LPL-activity in vivo. Wild-type and CB1-deficient mice
exhibited similar energy intakes. Energy expenditure, on
the other hand, was increased in CB1
-/- mice upon high-
fat feeding, resulting in lower adiposity and decreased
fat cell size. We therefore propose that the protection
against diet-induced adiposity in CB1
-/- mice is not
related to functional alterations in fat metabolism per se,
but rather results from increased energy loss by oxida-
tive and potentially non-oxidative pathways.
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Additional file 1: Table S1 Composition of experimental diets. Table
S2 Primer and probe sequences used for qPCR. Sequence and accessions
numbers of qPCR primers and probes used in these study. Figure S1 (A)
VO2,( B) VCO2 and (C) RER values during light and dark phases. Open
symbols, CB1
+/+ mice; closed symbols, CB1
-/- mice. Values are given as
means ± SEM for n = 5-7. (D) Gene expression levels in epididymal fat
tissue of 3-week old CB1
-/- and CB1
+/+ mice receiving regular chow. Open
bars, CB1
+/+ mice; closed bars, CB1
-/- mice. Values are given as means ±
SEM for n = 4-8. Table S3 Detailed indirect calorimetry data in CB1
+/+ and
CB1
-/- mice fed chow, a HF or a HF/FO diet during 6 weeks. Energy
expenditure and substrate utilization during dark and light phases,
expressed per mouse (upper part) or normalized for lean body mass
(lower part).
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